(E)-3-(3-(3,4-dimethoxyphenyl)-3-oxoprop-1-en-1-yl)benzonitrile | 1365644-29-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-3-(3-(3,4-dimethoxyphenyl)-3-oxoprop-1-en-1-yl)benzonitrile
• 英文别名: (E)-1-(3,4-dimethoxyphenyl)-3-(3-cyanophenyl)prop-2-en-1-one；3-[(E)-3-(3,4-dimethoxyphenyl)-3-oxoprop-1-enyl]benzonitrile
• CAS: 1365644-29-6
• 化学式: C₁₈H₁₅NO₃
• 分子量: 293.322
• InChiKey: KAMGTLAENWAMBY-SOFGYWHQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.47
• 重原子数：
  22.0
• 可旋转键数：
  5.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  59.32
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为产物：
  描述：

  3-氰基苯甲醛 、 3,4-二甲氧基苯乙酮 在 lithium hydroxide monohydrate 作用下， 以 乙醇 为溶剂， 反应 2.17h， 以78%的产率得到(E)-3-(3-(3,4-dimethoxyphenyl)-3-oxoprop-1-en-1-yl)benzonitrile
  参考文献：
  名称：

  Methoxychalcone inhibitors of androgen receptor translocation and function

  摘要：

  Androgen receptor activity drives incurable castrate-resistant prostate cancer. All approved antiandrogens inhibit androgen receptor-driven transcription, and in addition the second-generation antiandrogen MDV3100 inhibits ligand-activated androgen receptor nuclear translocation, via an unknown mechanism. Here, we report methoxychalcones that lock the heat shock protein 90-androgen receptor complex in the cytoplasm in an androgen-non-responsive state, thus demonstrating a novel chemical scaffold for antiandrogen development and a unique mechanism of antiandrogen activity. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2011.12.141

文献信息

• Design, Synthesis, and Biological Evaluation of Novel Allosteric Protein Disulfide Isomerase Inhibitors
  作者：Suhui Yang、Andrea Shergalis、Dan Lu、Anahita Kyani、Ziwei Liu、Mats Ljungman、Nouri Neamati

  DOI：10.1021/acs.jmedchem.8b01951

  日期：2019.4.11

  survival. To improve the potency of lead PDI inhibitor BAP2 (( E)-3-(3-(4-hydroxyphenyl)-3-oxoprop-1-en-1-yl)benzonitrile), we designed and synthesized 67 analogues. We determined that PDI inhibition relied on the A ring hydroxyl group of the chalcone scaffold and cLogP increase in the sulfonamide chain improved potency. Docking studies revealed that BAP2 and analogues bind to His256 in the b' domain of

  蛋白质二硫键异构酶 (PDI) 负责内质网 (ER) 中的新生蛋白质折叠，对胶质母细胞瘤的存活至关重要。为了提高 PDI 抑制剂 BAP2 (( E)-3-(3-(4-hydroxyphenyl)-3-oxoprop-1-en-1-yl)benzonitron) 的效力，我们设计并合成了 67 种类似物。我们确定 PDI 抑制依赖于查耳酮支架的 A 环羟基，并且磺酰胺链中 cLogP 的增加提高了效力。对接研究表明，BAP2 和类似物与 PDI 的 b' 结构域中的 His256 结合，而 His256 突变为 Ala 会消除 BAP2 类似物的活性。BAP2 和优化的类似物 59 具有适度的硫醇反应性；然而，我们建议 BAP2 类似物对 PDI 的抑制取决于 b' 结构域。重要的是，类似物抑制胶质母细胞瘤细胞生长，诱导 ER 应激，增加 G2M 检查点蛋白的表达，降低 DNA 修复蛋白的表达。总的来说，我们的结果支持抑制
• NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER
  申请人：The U.S.A. as represented by the Secretary, Department of Health and Human Services

  公开号：EP3333153A1

  公开（公告）日：2018-06-13

  Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I: wherein R1 to R5 and X1 to X5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.

  所公开的化合物是核受体调节剂，可作为雄激素受体的拮抗剂，例如，式 I 的化合物： 其中 R1 至 R5 和 X1 至 X5 如本文所述，以及其药学上可接受的盐、溶剂和立体异构体。此外，还公开了包含此类化合物的药物组合物，以及使用方法和癌症（包括前列腺癌、其他核受体介导的癌症和其他疾病）的治疗方法。
• Nuclear receptor modulators and their use for the treatment and prevention of cancer
  申请人：The United States of America, as represented by the Secretary, Department of Health and Human Services

  公开号：US10737995B2

  公开（公告）日：2020-08-11

  Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I: wherein R1 to R5 and X1 to X5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.

  所公开的化合物是核受体调节剂，可作为雄激素受体的拮抗剂，例如，式 I 的化合物： 其中 R1 至 R5 和 X1 至 X5 如本文所述，以及其药学上可接受的盐、溶剂和立体异构体。此外，还公开了包含此类化合物的药物组合物、使用方法以及癌症（包括前列腺癌）、其他核受体介导的癌症和其他疾病的治疗方法。
• Methoxychalcone inhibitors of androgen receptor translocation and function
  作者：Yeong Sang Kim、Vineet Kumar、Sunmin Lee、Aki Iwai、Len Neckers、Sanjay V. Malhotra、Jane B. Trepel

  DOI：10.1016/j.bmcl.2011.12.141

  日期：2012.3

  Androgen receptor activity drives incurable castrate-resistant prostate cancer. All approved antiandrogens inhibit androgen receptor-driven transcription, and in addition the second-generation antiandrogen MDV3100 inhibits ligand-activated androgen receptor nuclear translocation, via an unknown mechanism. Here, we report methoxychalcones that lock the heat shock protein 90-androgen receptor complex in the cytoplasm in an androgen-non-responsive state, thus demonstrating a novel chemical scaffold for antiandrogen development and a unique mechanism of antiandrogen activity. Published by Elsevier Ltd.